This research investigates why blocking an early asthma “alarmin” signal often fails as a treatment. Using mouse models, it reveals that environmental differences—particularly the microbiome—can bypass this signal and still drive asthma. Understanding microbiome health may help predict treatment success and lead to more personalized, effective asthma therapies.

This research targets the earliest stage of allergic and asthmatic immune reactions by blocking key cytokine “messages” sent from T cells to B cells. Using drug-discovery techniques, the project identifies compounds that prevent immune overreaction before symptoms begin, aiming to develop a new class of long-lasting preventative allergy and asthma treatments.